Destructive facial T-cell lymphoma: the difficulty in diagnosis of pyoderma-like processes.
Department of Dermatology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.
Lawrence E
LE
Gibson
Bethany R
BR
Hairston
Robert J
RJ
Belt
Rokea
R
el-Azhary
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D003951:Diagnostic Errors; D004317:Doxorubicin / Q000627:therapeutic use; D005153:Facial Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology*; D005260:Female; D005355:Fibrosis / Q000209:etiology; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D017114:Liver Failure, Acute / Q000209:etiology; D008175:Lung Neoplasms / Q000473:pathology / Q000556:secondary; D016399:Lymphoma, T-Cell / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology*; D008875:Middle Aged; D017511:Pyoderma Gangrenosum / Q000175:diagnosis; D014750:Vincristine / Q000627:therapeutic use
D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide